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We report a cisplatin and irinotecan combination in patients with biopsy-proven advanced pancreatic adenocarcinoma. Patients were
selected from a specialist centre and required good performance status (KPS470%), measurable disease on CT scan, and
biochemical and haematological parameters within normal limits. Based on a two-stage phase II design, we aimed to treat 22 patients
initially. The study was stopped because of the death of the 19th patient during the first treatment cycle, with neutropenic sepsis and
multiorgan failure. A total of 89 treatments were administered to 17 patients. Serious grade 3/4 toxicities were haematological
(neutropenia) 6%, diarrhoea 6%, nausea 7% and vomiting 6%. Using the clinical benefit response (CBR) criteria, no patients had an
overall CBR. For responses confirmed by CT examination, there was one partial response (5%), three stable diseases lasting greater
than 6 weeks (16%), with an overall 22% with disease control (PRþSD). The median progression-free and overall survival was 3.1
months (95% CI: 1.3–3.7) and 5.0 (95% CI: 3.9–10.1) months, respectively. Although this synergistic combination has improved the
response rates and survival of other solid tumours, we recommend caution when using this combination in the palliation of advanced
pancreatic cancer, because of unexpected toxicity.
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Once diagnosed, patients with pancreatic adenocarcinoma have an
average life expectancy of 16–20 weeks. Clinical management has
an emphasis on palliative support because of the poor prognosis
and the rapidly deteriorating quality of life due to the syndrome of
fatigue, weight loss, pain and jaundice (Wigmore et al, 1997;
Andreyev et al, 1998). Standard selection criteria, as used for most
other solid tumours, can often exclude a significant proportion of
pancreatic cancer patients, with trials reporting results in selected
patients with good performance status. Toxic treatments that
follow can lead to early withdrawal from studies, may worsen
otherwise the good quality of life and, in some instances, shorten
the duration of life. The use of low-toxicity agents, such as
gemcitabine and metalloproteinase inhibition, have had notable
success in terms of trial recruitment, patient compliance and
treatment tolerance (Carmichael et al, 1996; Burris et al, 1997;
Bramhall et al, 2001).
The 5-year survival rate for pancreatic cancer remains at
2% (Bramhall et al, 1995). Single-agent chemotherapy, such as
5-flurouracil, paclitaxel and gemcitabine, all result in radiological
response rates between 5 and 15% (Burris et al, 1997; Whitehead
et al, 1997). Combination chemotherapy, including drugs such as
cisplatin, 5-FU, adriamycin and gemcitabine, have generally
improved the response rates slightly, at the expense of increasing
toxicity in some combinations (Cascinu et al, 1996; Evans et al,
1996; Hidalgo et al, 1999). Aside from the differences in patient
selection, one problem with the interpretation of these studies is
the reliability of radiological response, mainly because of the dense
fibrotic reaction that often occurs within pancreatic tumours
(Ahlgren, 1996). As a result, survival data are often quoted in
combination with surrogate factors, for example, the clinical
benefit response (CBR). The latter incorporates a scoring system
for positive and negative changes in pain, performance status and
weight, and has been an important tool in establishing gemcitabine
efficacy (Rothenberg et al, 1996a).
Here we report the activity and toxicity of the drug combination,
irinotecan and cisplatin, in previously untreated patients with
advanced pancreatic cancer. This combination has been shown to
generate significant short-term radiological response rates and
improvement in survival in solid tumours, most notably in small-
cell lung cancer (Noda et al, 2002, Ilson et al, 2003; Souid et al,
2003).
Irinotecan is a camptothecin analogue and topoisomerase I
inhibitor with a highly active metabolite (Sn38). This agent has
demonstrated improved survival in metastatic 5-FU refractory
colorectal cancer (Cunningham and Glimelius, 1999; Rothenberg
et al, 1999). Laboratory studies show high response rates of
pancreatic tumour cells in culture and in xenograft studies
(Takeda et al, 1992; Bissery et al, 1996). Single-agent phase II
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lstudies of irinotecan in pancreatic carcinoma (dose intensity
100mgm
 2week
 1) have shown typical response rates of around
10%, again similar to other single agents (Wagener et al, 1995;
Armand et al, 1996). There are now data showing significant
synergy between cisplatin and irinotecan in lung cancer cell lines
in vitro (Kanzawa et al, 2001). However, there are no published
data concerning cisplatin and irinotecan alone in advanced
pancreatic cancer, although other agents have been successfully
combined with irinotecan in this disease, for example, gemcitabine
(de Jonge et al, 2000; Kozuch et al, 2001; Rocha Lima et al, 2002;
Slater et al, 2002).
MATERIAL AND METHODS
Patient selection and study design
Eligible patients were chemotherapy naı ¨ve (418 years), and had
pancreatic adenocarcinoma diagnosed by histology with measur-
able disease on CT scan. Karnofsky performance status
(KPS)470%, either stent insertion or hepato-jejunostomy for
biliary drainage, bilirubin o1.5  upper limit of the normal
(o35mmoll
 1), AST o5  upper limit of the normal, GFR
460mlmin
 1 based on Cockcroft formula and confirmed by
creatinine clearance in borderline cases, neutrophils
41.5 10
9l
 1 and normal blood count profile with no clinical
history of inflammatory bowel disease or previous malignancy
(except non-melanoma skin cancer and in situ cervical carcino-
ma). The study was approved by the South Birmingham Local
Ethics Committee and all patients gave written informed consent.
All patients were requested to complete a pain inventory of all
analgesic medication, and pain was assessed using the Wisconsin
brief pain questionnaire and visual analogue scale (assessed every
evening at the same time).
The end points of this study were the radiological response rate
(CRþPR), disease control (CRþPRþSD), overall survival
(defined as the time from entry into the trial to the date of death
or censor), progression-free survival (PFS) at 3 months (defined as
the time from entry into the trial to the first objective
documentation of progression), CBR and toxicity. Clinical benefit
response was assessed as recommended by Rothenberg et al
(1996b). In summary, primary measures were defined as 420%
increase in performance status lasting greater than 4 weeks from a
baseline score of o70%, 450% reduction in morphine-equivalent
analgesic consumption for 4 weeks from a baseline of 410mg
morphine equivalent per day, 450% improvement in pain scores
from baseline 420mm (visual analogue scale), with a secondary
measure of 47% increase in weight sustained for 44 weeks. No
CBR was assumed for patients who progressed within 4 weeks.
The aim was to recruit an initial 22 patients into the first stage of
a two-stage Gehan design (based on 90% power and estimated 10%
response rate), with the number of further patients recruited to
stage two based on patient response in stage one. The trial was
terminated at 19 patients following a presumed toxic death.
Treatment
Irinotecan (a gift from Aventis) with atropine sulphate (300mg)
prophylaxis (Gandia et al, 1993) was administered over 90min
following hydration (500ml N/salineþ20mmol KClþmagne-
magnesium) over 30min and cisplatin (25mgm
 2) administered
over 30min, on days 1 and 8 of a 21-day cycle. (The calculated
dose intensity for irinotecan is approximately 50% of that utilised
in single-agent Phase I studies, 46mgm
 2week
 1.) A maximum of
five cycles could be administered (15 weeks), with weekly patient
visits for clinical examination, toxicity evaluation, FBC, biochem-
istry, weight (prior to hydration), pain inventory and performance
status assessment (worser of two scores determined independently
by two observers). Loperamide and ciprofloxacin were provided
for prophylaxis against irinotecan-induced delayed diarrhoea, as
advised by the manufacturer. Chemotherapy was administered
only if KPSX70%, neutrophils41.5 10
9/l and all other haema-
tological and liver functions tests remained within normal limits. If
either grade 3–4 diarrhoea or grade 4 neutropenia, or grade 3
neutropenia and infection occurred, then irinotecan dose was
reduced to 35mgm
 2 (diarrhoea and neutropenia) and cisplatin
reduced to 20mgm
 2 (neutropenia only) in all subsequent cycles.
All other toxicities were recorded weekly, and any greater than
grade 2 were treated with supportive care and a maximum delay in
chemotherapy of 2 weeks. Continuous treatment with steroids was
discouraged unless the patient had been on a constant main-
tenance dose for 2 weeks prior to trial entry, or there was
persistent and severe loss of appetite following chemotherapy,
severe liver capsular pain or there was chemotherapy-related
delayed nausea and vomiting.
Response and toxicity
Staging abdominal CT scans with contrast enhancement were
performed within 2 weeks of the start and end of chemotherapy
following a minimum of two cycles of treatment, and every 4–6
weeks thereafter, unless there was obvious clinical evidence of
progression. The response evaluation criteria in solid tumours
(RECIST) criteria were employed to immediately assess CT scans
and to guide subsequent management, and all CT scans were again
reviewed independently by one radiologist after closure of the
study (Therasse et al, 2000). Toxicity was assessed after each
treatment and graded using the National Cancer Institute of
Canada Clinical Trials group (NCIC-CTG) expanded common
toxicity criteria (CTC version 1).
RESULTS
A total of 19 out of the 22 patients planned were recruited into
this study from a single institution and analysed by intention to
treat. One patient was excluded from response and toxicity
analysis from the outset due to a rapid deterioration of a
concurrent clinical condition that precluded consent to
chemotherapy. Patient characteristics for the 18 remaining patients
are shown in Table 1. In summary, the majority of patients had a
KPS 490% at study entry (78%), metastatic disease (67%, stage
IVB) from a pancreatic head primary (83%), and had not received
previous chemotherapy or radiotherapy (one patient had previous
immunisation against gastrin, which completed 6 weeks prior
to study entry). One patient was taking steroids at entry, five
patients had previous bypass gastro-jejunostomy and nine patients
had concurrent medical conditions: ankylosing spondyli-
tisþdiabetes (1), bilateral deep venous thrombosis (1), diabetes
(2), epilepsy (1), hypertension (3), controlled chronic schizo-
phrenia (1). Delay between histological diagnosis and entry
into the trial was approximately 4 weeks, but had a wide range.
The first treatment was usually on the day of entry to the trial for
15 (83%) patients (two patients starting 4 and 7 days after entry
and one consented patient did not receive treatment due to
deterioration of performance status on the day of treatment). In
all, 17 patients received a total of 89 treatments of combination
chemotherapy between March 2000 and June 2001. Altogether, 75
(84%) of treatments were full dose (70mgm
 2 irinotecan,
25mgm
 2 cisplatin). In 14 cases, doses were reduced (14 doses
to 35mgm
 2 irinotecan, 20mgm
 2 cisplatin) and six patients
missed a total of 10 treatments because of toxicity. The actual
mean dose intensity per patient of chemotherapy was 37.0 (range
17.5–46.7, median 40.8, protocol 46.7) mgm
 2week
 1 for
irinotecan and 13.7 (range 7.5–16.7, median 14.6, protocol
16.7)mgm
 2week
 1 for cisplatin.
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In all, 15 of the 18 patients had died at the time of analysis. The
three alive patients were censored in the survival analysis at 6, 6.5
and 16 months. The median overall survival was 5.0 (95% CI: 3.9,
10.1) months and median PFS was 3.1 (95% CI: 1.3, 3.7) months.
All patients, but one, had stable disease or had progressed either
radiologically or clinically within the 15 weeks study duration.
Radiological response
Seven (39%) patients did not undergo post-treatment scans
because of clinical evidence of progression (one patient with
intrahepatic cholestasis from metastasis confirmed on ultrasound
examination, four patients with a combination of rapid loss of
weight, increased pain and rapid deterioration of performance
status, one pulmonary embolism and one death). The remaining 11
patients had pre- and post-treatment CT scans with repeat post-
treatment scans after at least 6 weeks. Using RECIST criteria, there
were no complete responders, one partial response of low volume
disease in pancreatic body and liver (PR¼5%), three with stable
disease, who were stage IVA (n¼2) and IVB (n¼1) (SD¼17%,
PRþSD¼22%), and seven (39%) with progressive disease.
Clinical benefit response (CBR)
Only one patient had a positive response to pain intensity
(negative to analgesia), five patients had a positive/stable response
to analgesia (all nonassessable for pain intensity), five patients
were negative for both pain scores. The majority of patients were
not eligible for KPS assessment, as their baseline performance
status was above 70%, and were stable for weight, meaning that no
CBR were detected using the strictly applied criteria of Rothen-
berg.
Toxicity
Almost all grade 3 and 4 toxicity occurred within the first 4 weeks
of treatment (Table 2). Of the 89 doses administered, five (6%)
were associated with grade 3/4 diarrhoea, five (6%) with grade 3/4
haematological toxicity (neutropenia), six (7%) with grade 3/4
nausea and 5 (6%) with grade 3/4 vomiting.
The trial was stopped because of a serious adverse event
classified as a toxic death, even though postmortem was refused:
concurrent grade 4 diarrhoea, nausea, vomiting, pain and
haematological toxicity, resulting in multiorgan failure and death.
The patient had liver metastasis and a large head of pancreas
primary encasing superior mesenteric vessels. Obstructive jaun-
dice was slow to clear following biliary stent insertion prior to trial
entry, although within normal limits on the day of chemotherapy
administration. Emergency admission occurred after week 2 as a
result of acute abdominal pain, hypotension and neutropenic
fever. Neither the pain nor the fever responded to antibiotics, and
the patient died of a presumed intra-abdominal catastrophic event,
multiorgan failure and neutropenic sepsis.
Three additional serious adverse events were reported and all
disease related (pulmonary embolus, deep venous thrombosis and
gastrointestinal bleed after 1, 2 and 10 weeks (1, 2 and 7 doses) of
treatment, respectively). Grade 3 and 4 neutropenia occurred
during weeks 2–4 of treatment and were often associated with
nausea and vomiting. In two patients, this correlated with slightly
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CTC Grade N (%) N (%)
Diarrhoea
1/2 10 (56%) 17 (19%)
3 2 (11%) 1 (1%)
4 2 (11%) 4 (5%)
Haematological
1/2 10 (56%) 28 (32%)
3 3 (17%) 3 (3%)
4 2 (11%) 2 (2%)
Nausea
1/2 11 (61%) 23 (26%)
3 4 (22%) 4 (5%)
4 2 (11%) 2 (2%)
Vomiting
1/2 7 (39%) 14 (16%)
3 2 (11%) 2 (2%)
4 3 (17%) 3 (3%)
Other
1/2 11 (61%) 39 (44%)
3 1 (6%) 1 (1%)
4 1 (6%) 1 (1%)
Nontoxic SAE 3 (17%) 3 (3%)
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lhigher bilirubin levels in the normal range at entry into the study
(not shown). This suggested that either intrahepatic cholestasis
from metastasis or slow recovery from obstructive jaundice may
have increased the half-life of Irinotecan metabolites (Sn38) and
resulted in increased susceptibility to toxicity. ‘Other’ toxicities
reported were 21, Grade 1 and 18, Grade 2 events: pain (5),
alopecia (9), constipation (8), tiredness (4), appetite (1), oral (6),
skin (1), pulmonary embolus and atrial fibrillation (1), transient
raised creatinine (1), steatorrhoea (2), and upper respiratory tract
infection (1).
DISCUSSION
Our results show that the majority of patients with advanced
pancreatic adenocarcinoma and good performance status can
tolerate an irinotecan and cisplatin combination at modest doses,
but that this combination appears not all that active, with response
rates that are in line with other chemotherapy combinations in this
disease. However, the disadvantage of this combination may be the
severe toxicity in patients with advanced pancreatic cancer, as
others have reported (Slater et al, 2002), which may be the result of
either interindividual variability in drug metabolism or decreased
biliary drainage from the liver following obstructive jaundice.
Despite the small size of this study, we urge caution in the
adoption of this combination in pancreatic cancer, even though
some patients appeared to respond to treatment. Furthermore,
recent reports also highlight the unpredictable toxicity that can
occur with irinotecan using dosing based on body weight, which
suggests that the use of a fixed dosing of this agent may be
preferential (Mathijssen et al, 2002). If this combination were used
again in advanced pancreatic cancer, we would dose irinotecan at a
low level for at least the first cycle and judge dose escalation by
nadir blood counts. We would also wish to obtain more
information about the appropriate selection of patients prior to
treatment (see below). Aside from unpredictable toxicity, we note
that the haematological toxicity from this combination appears no
different from single-agent irinotecan or combinations of irinote-
can and gemcitabine (Wagener et al, 1995; Armand et al, 1996;
Rocha Lima et al, 2002).
Radiological response rates and survival in this study are
compatible with other single agent and combination treatments.
Clinical benefit response criteria remain subjective and may be
difficult to compare across studies depending on modified criteria,
so we chose to follow the original criteria (Cascinu et al, 1996;
Burris et al, 1997; Rocha Lima et al, 2002). With the modest trial
selection parameters chosen here, almost all patients who tolerated
full-course treatment had preserved weight and performance
status, and controlled pain over the study period (not shown).
While these patients are better at tolerating a 15-week chemother-
apy course, they tended not to contribute to a CBR analysis, as
strictly judged by the original published criteria of Rothenberg et al
(1996b). The main reason for a lack of detectable benefit was the
magnitude and duration of improvement from the baseline level at
trial entry. Furthermore, the selection criteria for most trials lead
to bias, as enrollment of patients with good performance status,
with little pain and weight loss, are selected. Any change in CBR
may be unrepresentative of the total population of patients
presenting with advanced pancreatic cancer. A further selection
bias may be related to the extent of disease, as patients with
locoregional disease tend to have a prolonged survival (Bramhall
et al, 2001). Thus, because we have adopted a Phase II approach
with small numbers of patients, we cannot exclude a role for this
combination in the treatment of a subgroup of patients that might
tolerate treatment with minimal toxicity even at higher doses, and
which may also have a higher response rate. One approach that
might avoid continued reporting of negative Phase II studies such
as this might be to attempt to optimise current combination
therapy to clinical subgroups of patients with advanced pancreatic
adenocarcinoma. For example, good performance status patients
with locoregional disease may tolerate high-dose combination
treatments and gain most palliative benefit from their use. The
assessment of palliative benefit vs toxicity for new combinations of
chemotherapy and biological therapy in pancreatic cancer may
require the stratification of patients in future phase II trials.
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